Current ideas on vulvovaginal candidiasis
- Authors: Kulikov I.A.1,2, Ovsyannikova T.V.3
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology
- Peoples’ Friendship University of Russia
- Issue: No 10 (2018)
- Pages: 123-128
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/248352
- DOI: https://doi.org/10.18565/aig.2018.10.123-128
- ID: 248352
Cite item
Open Access
Access granted
Abstract
The article presents an explanation of the relevance of using regimens incorporating highly effective antimycotics in modern society, which is dictated by the lifestyle of large cities and the modern generation. After the symptoms of the disease disappear, many patients discontinue a prescribed drug treatment regimen on their own, interrupting the full cycle, which can lead to recurrences and unresponsiveness to treatment in the future.
Full Text
About the authors
Ilya A. Kulikov
I.M. Sechenov First Moscow State Medical University (Sechenov University); Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and PerinatologyPhD, MD, obstetrician-gynecologist, Department of Aesthetic Gynecology and Rehabilitation; Associate Professor of the Department of Obstetrics, Gynecology, Perinatology and Reproductive Medicine
Tamara V. Ovsyannikova
Peoples’ Friendship University of Russia
Email: dr.otoma@yandex.ru
MD, Professor of the Department of Obstetrics and Gynecology
References
- Малова И.О., Рахматулина М.Р., Соколовский Е.В. Федеральные клинические рекомендации по ведению больных урогенитальным кандидозом. М.: Российское общество дерматовенерологов и косметологов, Российское общество акушеров-гинекологов; 2016.
- Moran P., Coleman D., Sulivan D. Candida albicans versus Candida dubliniensis: why is C. albicans more pathogenic? Int. J. Microbiol. 2012; 2012: 205921.
- Papon N., Courdavault V., Clastre M., Bennett R.J. Emerging and emerged pathogenic Candida species beyond the Candida albicans paradigm. PLoS Pathog. 2013; 9(9): e1003550.
- Butler G. Fungal sex and pathogenesis. Clin. Microb. Rev. 2010; 23(1): 140-59.
- Butler G., Lorenz M., Gow N. Evolution and genomics of the pathogenic Candida species complex. In: Sibley L.D., Howlett B.J., Heitman J., eds. Evolution of virulence in eukaryotic microbes. Wiley-Blackwell; 2012: 404-21.
- Федеральные клинические рекомендации по ведению больных урогенитальным кандидозом. Акушерство и гинекология. 2016; 4(Приложение): 50-6.
- Серов В.Н., Буралкина Н.А., Борисенко М.Ю., Мамедова Ф.Ш. Клиническая эффективность флуконазола в лечении вульвовагинального кандидоза. Медицинский Совет. 2016; 2: 60-3. https://doi.org/10.21518/2079-701X-2016-2-60-63
- Воронова О.А., Зильберберг Н.В., Кузнецова Ю.Н., Евстигнеева Н.П. Алгоритм выбора терапии больных урогенитальным кандидозом. Успехи современного естествознания. 2015; 2: 21-5.
- Jacobsen I.D., Wilson D., Wächtler B., Brunke S., Naglik J.R., Hube B. Candida albicans dimorphism as a therapeutic target. Expert Rev. Anti Infect. Ther. 2012; 10(1): 85-93.
- Pfader M.A. Antifungal drug resistance mechanisms, epidemiology and consequences for treatment. Am. J. Med. 2012; 125(1, Suppl.): S3-13.
- Rezaei Z., Khabnadideh S., Pakshir K., Hossaini Z., Amiri F., Assadpour E. Design, synthesis and antifungal activity of triazole and benzotriazole derivatives. Eur. J. Med. Chem. 2009; 44(7): 3064-7.
- Workowski K.A., Bolan G.A.; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm. Rep. 2015; 64(RR-03): 1-137.
- Rotem R., Fishman B., Daniel S., Koren G., Lunenfeld E., Levy A. Risk of major congenital malformations following first-trimester exposure to vaginal azoles used for treating vulvovaginal candidiasis: a population-based retrospective cohort study. BJOG. 2018; 125(12): 1550-6.
Supplementary files
